The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

HIV activist Solly Nduku was recently elected to the top civil society position at the South African National Aids Council.

People with HIV are more likely to have severe premenstrual syndrome (PMS) symptoms than others, such as: In the United States, about 2% of transgender people make up new HIV diagnoses.